Altimmune aims to build Momentum in obesity

Altimmune aims to build Momentum in obesity

Source: 
EP Vantage
snippet: 

Novo Nordisk’s Wegovy has revolutionised the treatment of obesity in the short time it has been on the market, and Lilly’s Mounjaro is expected to do even better if – or, more likely, when – it gets the nod this year.

Of the many groups following these two colossi, one of the hottest hopes is Altimmune, whose incretin pemvidutide is due to yield interim data from a mid-stage trial towards the end of March.